Traws Pharma Q2 net loss narrows to $0.9M; cash drops to $13.1M; Phase 2 COVID study planned

Traws Pharma, Inc.

2025-Q2 EPS reported $1.95 revenue$2,790,000

Net loss of $0.9M ($0.11/share) vs. $123.1M loss in Q2 2024 which included $117.5M acquisition charge.
Revenue $2.7M (vs. $57K) from deferred revenue on mutual termination of an oncology license.
Cash, cash equivalents and investments $13.1M as of June 30, down from $21.3M at Dec 31, 2024.
Phase 2 ratutrelvir (COVID) study submitted to HREC in Australia; results expected by year-end 2025.
Bird flu Phase 2 study deferred; BARDA stockpile discussions continue; Charles Parker named Interim CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.